

Title: Alzheimer Disease Overview *GeneReview* – Table 2  
 Author: Bird TD  
 Date: December 2018

**Table 2. Alzheimer Disease Susceptibility Genes**

<b>Gene</b>	<b>Potential Functional Contribution to Alzheimer Disease Risk</b>
<i>ABCA7</i>	Efflux of phospholipids & phagocytosis
<i>AKAP9</i>	Kinase anchor protein (association in African Americans only)
<i>BIN1</i>	Clathrin-mediated endocytosis
<i>CASS4</i>	Scaffolding protein of unknown function (in <i>Drosophila</i> ortholog binds to CD2AP ortholog)
<i>CD2AP</i>	Cytoskeletal reorganization & vesicle movement A $\beta$ clearance; protection against tau toxicity
<i>CD33</i>	Cell-cell interactions & cell functions in the innate & adaptive immune systems
<i>CLU</i>	Chaperone function; regulation of cell proliferation
<i>CR1</i>	Regulation of complement activation
<i>EPHA1</i>	Modulates cell migration, axon guidance, & synapse development & plasticity during brain development
<i>FERMT2</i>	Actin assembly & cell shape modulation
<i>HLA-DRB5/DRB1</i>	Immune system regulation
<i>INPP5D</i>	Regulation of gene expression & posttranslational modification of proteins, microglial & myeloid function
<i>MEF2C</i>	Synaptic plasticity
<i>MS4A6A/MS4A4E</i>	Immune modulation
<i>PICALM</i>	Trafficking of synaptic vesicle proteins
<i>PLD3</i>	Phospholipase
<i>PTK2B</i>	Ion signaling & induction of long-term potentiation in hippocampal CA1 neurons
<i>SORL1</i>	Vesicle trafficking
<i>UNC5C</i>	Related to axon extension & cell migration during development

Based on reviews by Naj et al [2014], Del-Aguila et al [2015], Ridge et al [2016], Van Cauwenberghe et al [2016], and Yokoyama et al [2016]

## References

Del-Aguila JL, Koboldt DC, Black K, Chasse R, Norton J, Wilson RK, Cruchaga C. Alzheimer's disease: rare variants with large effect sizes. *Curr Opin Genet Dev.* 2015;33:49-55.

Naj AC, Jun G, Reitz C, Kunkle BW, Perry W, Park YS, Beecham GW, Rajbhandary RA, Hamilton-Nelson KL, Wang LS, Kauwe JS, Huentelman MJ, Myers AJ, Bird TD, Boeve BF, Baldwin CT, Jarvik GP, Crane PK, Rogaeva E, Barmada MM, Demirci FY, Cruchaga C, Kramer PL, Ertekin-Taner N, Hardy J, Graff-Radford NR, Green RC, Larson EB, St George-Hyslop PH, Buxbaum JD, Evans DA, Schneider JA, Lunetta KL, Kamboh MI, Saykin AJ, Reiman EM, De Jager PL, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Martin ER, Haines JL, Mayeux RP, et al. Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. *JAMA Neurol.* 2014;71:1394-404.

Ridge PG, Hoyt KB, Boehme K, Mukherjee S, Crane PK, Haines JL, Mayeux R, Farrer LA, Pericak-Vance MA, Schellenberg GD, Kauwe JSK, et al. Assessment of the genetic variance of late-onset Alzheimer's disease. *Neurobiol Aging.* 2016;41:200.e13-200.e20.

Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. *Genet Med.* 2016;18:421-30.

Yokoyama JS, Wang Y, Schork AJ, Thompson WK, Karch CM, Cruchaga C, McEvoy LK, Witoelar A, Chen CH, Holland D, Brewer JB, Franke A, Dillon WP, Wilson DM, Mukherjee P, Hess CP, Miller Z, Bonham LW, Shen J, Rabinovici GD, Rosen HJ, Miller BL, Hyman BT, Schellenberg GD, Karlsen TH, Andreassen OA, Dale AM, Desikan RS, et al. Association between genetic traits for immune-mediated diseases and Alzheimer disease. *JAMA Neurol.* 2016;73:691-7.